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Sporadic inclusion body myositis (sIBM) is the commonest idiopathic inflammatory muscle disease in people over
50 years old. It is characterized by slowly progressive muscle weakness and atrophy, with typical pathological
changes of inflammation, degeneration and mitochondrial abnormality in affected muscle fibres. The cause(s) of
sIBM are still unknown, but are considered complex, with the contribution of multiple factors such as environmental
triggers, ageing and genetic susceptibility. This review summarizes the current understanding of the genetic
contributions to sIBM and provides some insights for future research in this mysterious disease with the advantage of
the rapid development of advanced genetic technology. An international sIBM genetic study is ongoing and
whole-exome sequencing will be applied in a large cohort of sIBM patients with the aim of unravelling important
genetic risk factors for sIBM.
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Sporadic inclusion body myositis (sIBM) is the commonest
form of idiopathic inflammatory myopathy among individ-
uals aged over 50 [1]. It has a male predominance and a
prevalence of 1–71 people per million inhabitants has been
reported in different populations, rising up to 139 per
million among people over 50 years old (Table 1) [1-10].
These figures may be substantially underestimated due to
frequent initial misdiagnosis of this disease [11-13]. Clinic-
ally, sIBM is characterised by progressive quadriceps
femoris and deep finger flexors weakness and atrophy
[11,12]. Many patients become wheelchair dependent and
severely disabled 10–15 years after symptom onset, al-
though disease progression is heterogeneous [12,13].
Dysphagia, due to oesophageal and pharyngeal muscle
involvement, affecting up to 80% of sIBM patients, can
be a significant problem predisposing to malnutrition,
pulmonary aspiration and pneumonia [11-13]. Muscle
tissue in sIBM is characterised by the presence of inflam-
matory and degenerative features. Inflammatory features in-
clude endomysial inflammation, partial invasion (invasion* Correspondence: q.gang@ucl.ac.uk
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regulation of major histocompatibility complex (MHC)
class I [14]. Degenerative features include the formation
of rimmed vacuoles, tubulofilaments seen on electron
microscopy and the accumulation of many myotoxic
proteins (including amyloid, p62 and TAR DNA-binding
protein-43 (TDP-43)), termed as ’inclusions’ [15]. The ob-
servation of ragged-red, cytochrome c oxidase (COX) defi-
cient and succinate dehydrogenase positive fibres reflects
mitochondrial changes in sIBM muscle tissue [16].
The clinical diagnosis of sIBM is confirmed by muscle
biopsy assisted by the clinical phenotype, electromyog-
raphy (EMG), determination of serum muscle-enzyme
levels and muscle imaging with MRI [11]. Currently, the
Griggs Criteria [17,18], the European Neuromuscular
Centre (ENMC) Criteria [19,20] and the MRC Centre
for Neuromuscular Diseases Criteria [21,22] are the most
widely used diagnostic criteria for sIBM. However, the
aetiology of sIBM is still unclear and no effective treat-
ment is available [11,23].
sIBM is a complex disease. The primary pathogenic
mechanism is still hotly debated and it is believed that
many factors including environmental factors contribute
to the disease process. There are many clinically and/or
histologically sIBM-like muscle diseases with known
genetic defects, which may provide clues to understandtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Prevalence of sporadic IBM in different populations
Study Region Diagnostic criteria Prevalence
(per million population)
Prevalence > 50 yrs
(per million population)
Lingberg et al. [2] Sweden Biopsy and clinical data 2.2 n/a
Kaipiainen-Seppanen and Aho [4] Finland Not mentioned 0.9 n/a
Philips et al. [5] Australia Griggs et al. criteria 9.3 35.3
Badrising et al. [3] Netherlands ENMC criteria 4.9 16
Felice and North (Connecticut, USA) [6] Connecticut, USA Griggs et al. criteria 10.7 28.9 (>45 yrs)
Needham et al. [1] Western Australia Clinical and biopsy criteria 14.9 51.2
Wilson et al. [7] Olmsted County, USA Griggs et al. criteria 71 n/a
Oflazer et al. [8] Istanbul, Turkey Own criteria from the study
(biopsy and clinical data)
1.0 6.0
Suzuki et al. [9] Japan Clinical and biopsy criteria 1.3 (in 1991) n/a
9.8 (in 2003) n/a
Tan et al. [10] South Australia Biopsy and clinical data 50.5 139.3
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hensively summarize known and candidate genetic suscep-
tibility risk factors for sIBM.
Muscle disorders similar to sIBM
Familial inclusion body myositis
There are several IBM case reports of two or more affected
siblings in the same family [24-26] and one report of af-
fected twins [27]. Because of the clinical and histological
similarities with sIBM these cases have been called familial
inclusion body myositis (fIBM). Human leukocyte antigen
(HLA) class II genotypes were reported in a strong asso-
ciation with some families, particularly the DR3 allele
(DRB*0301/0302) in four western families [24,25] and
the DR15(2)/DR4 (DRB1*1502/0405) in two Japanese sisters
[26]. The fIBM and sIBM share not only similar clinical,
biological, MRI and histopathological features but also simi-
lar genetic markers, which indicate the possibility that the
two subsets of IBM may share the same susceptibility deter-
minants to the disease development and also highlight the
genetic predisposition for sIBM pathogenesis.
Hereditary inclusion body myopathies
Hereditary inclusion body myopathies (hIBM) include
several autosomal-recessive and autosomal-dominant
muscle disorders with various clinical presentations, but
with a number of pathological features similar to those of
sIBM, including rimmed vacuoles, protein accumulations
and tubulofilaments on electron microscopy. Patients with
hIBM can be distinguished from sIBM by the earlier age
of onset, rarity of inflammatory features and negative MHC
class I expression, hence the term ‘myopathy’ instead of
‘myositis’ [28]. The hIBM can be grouped according to their
mode of inheritance and genetic mutations (see hIBM
subtypes in Table 2, and details in a previous IBM genetics
review [29]).Other rimmed vacuolar myopathies
Beyond the above conditions, there are various other
neuromuscular disorders showing rimmed vacuoles in
the muscle tissue, which make the differential diagno-
sis of sIBM even wider. Mutated genes have also been
found in these called ‘rimmed vacuolar myopathies’, such
as oculopharyngeal muscular dystrophy (OMIM#164300),
X-linked recessive Emery-Dreifuss muscular dystrophy
(OMIM#310300), limb girdle muscular dystrophy (LGMD)
type 2G (OMIM#601954), LGMD type 1A (OMIM#159000),
LGMD type 1G (OMIM#609115), and rigid spine syndrome
(OMIM#602771) [29]. Some intracellular Alzheimer’s-like
protein accumulations, including amyloid proteins, amyloid-
β Protein Precursor (AβPP), phosphorylated tau and
presenilin-1, among others, have been found in extensive
overlap between sIBM and myofibrillar myopathies [31].
Overall, these common features raise the possibility that
sIBM and these diseases share certain etiologic factors.
Indeed, a recent study [32], reported that the p.V805A
variant in MYH2 (gene associated with hIBM3) signifi-
cantly increased the risk of developing sIBM (RR = 12.2).
However, none of the patients with that variant reported
joint contractures or external ophthalmoplegia, a family
history of IBM or consanguineous marriage [32]. This was
the first report of a MYH2 gene mutation described in
non-familial cases. Immunohistochemical studies of
myosin heavy chain isoforms showed atrophy or loss of
muscle fibres expressing myosin heavy chain IIa or IIx,
which may provide important clues for establishing the
pathogenicity of this variant. In the same study, a novel
missense mutation c.1719G > A (p.V566M) in the LIM
domain binding 3 gene (LDB3, also known as ZASP;
causative gene for zaspopathy, a subtype of myofibrillar
myopathies), coding for Z-band alternatively spliced
PDZ-motif-containing protein, was reported in one of the
patients [32]. This finding indicates LDB3 mutations might
Table 2 Hereditary inclusion body myopathy subtypes (further detailed by Needham et al. [29])
Hereditary IBM (hIBM) subtypes OMIM# Disease inheritance Genes Function of coding proteins
Inclusion body myopathy 2 -
hIBM2 (distal myopathy with
rimmed vacuoles -DMRV/Nonaka
myopathy)
600737 (605820) Autosomal-recessive UDP-N-acetylgucosamine-2-
epimerase/N-acetylmannosamine
kinase (GNE) gene
A rate-limiting enzyme in the sialic
acid biosynthetic pathway, involved
in sialylation of muscle glycoproteins,
and cellular homeostasis
A leukoencephalopathy and a
vacuolar myopathy resembling IBM
n/a Autosomal-recessive Laminin alpha 2 (LAMA2)
gene [30]
An extracellular protein of basement
membrane, mediates the attachment,
migration, and organization of cells into
tissues during embryonic development
hIBM with congenital joint
contractures, ophthalmoplegia
and rimmed vacuoles – hIBM3
605637 Autosomal-dominant Myosin heavy chain IIa (MYH2;
previously known as MHCIIa)
gene
A member of Class II or conventional
myosin heavy chains, functions in
skeletal muscle contraction
Inclusion body myopathy with
early-onset Paget’s disease of the
bone (PDB) and frontotemporal
dementia (FTD) (IBMPFD)
167320 Autosomal-dominant Valosin-containing protein
(VCP) gene
A member of the ‘ATPases associated
with a variety of activities (AAA-ATPase)’
superfamily, is involved in a variety of
cellular activities, such as cell cycle control,
membrane fusion and the ubiquitin-
proteasome degradation pathway
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in the disease observed in this patient. Further studies with a
larger number of cases will be needed to clarify the contribu-
tion of these genes to the pathogenesis of sIBM. In addition,
investigations should be carried out on more hereditary my-
opathies candidate genes, including α-B crystalline (CRYAB),
dystrophin (DMD) and myotilin (MYOT) in the future.
Pathogenesis of sIBM and its predisposing genetic
factors
Currently there are two most popular theories for the
pathogenesis of sIBM – an autoimmune pathway and a
degeneration pathway. In addition, ageing is also considered
an important factor contributing to mitochondrial abnor-
malities (Figure 1).Figure 1 Possible pathogenic pathways of sIBM – multifactorial mech
pathway constitute the two most popular theories for the pathogenesis of
mitochondrial dysfunction in result of oxidative stress in the muscle tissue.
and how these potential pathways interact. Predisposing genes could alsoThe theory of an inflammation pathway stands for viral
or inflammatory triggering factors leading to the clonal ex-
pansion of CD8+ T cells and T cell-mediated cytotoxicity,
which ultimately result in damage or death of muscle fibres
[33]. This theory is supported by the increased occurrence
of sIBM in the presence of autoimmune disorders and HIV
and HTLV-1 infection [34]. Degenerative changes and
endoplasmic reticulum (ER) stress are considered as
secondary mechanisms induced by increased intracellular
cytokines and chemokines [33]. The degree of mitochon-
drial changes and muscle atrophy were suggested to be
strongly correlated with the severity of inflammation in a
recent study [35].
However, sIBM is poorly responsive to even vigorous
immunosuppression. Even where there is histopathologicalanisms involved. An inflammation pathway and a degeneration
sIBM. Ageing is also considered an important factor contributing to
However, it is still not clear which is the primary cause of the disease,
contribute to the development and progression of the disease.
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accompanied by clinical improvement. Therefore, some
investigators are supporting a degenerative hypothesis
over inflammation as the primary pathogenesis of sIBM.
The identification of aberrant protein aggregates in sIBM
vacuolated muscle fibres has shown the remarkable paral-
lels of those features in brain tissue of Alzheimer’s disease
(AD) and Parkinson’s disease with Lewy bodies. This
theory suggests that inflammation is secondary to the
degeneration-associated processes in sIBM muscle fibres
[36] including: 1) multiple protein aggregates [37], 2)
abnormal accumulation of lipoprotein receptors and
free cholesterol [38], 3) oxidative stress [39], 4) inhib-
ition of the ‘ubiquitin-proteasome system’ (UPS) [40],
5) endoplasmic reticulum stress [41], and 6) impaired
autophagy-lysosome pathway [41]. Furthermore, myonuc-
lear disintegration is also involved in the pathogenic
process leading to the formation of rimmed vacuoles.
This results in a severe consequence that is a progres-
sive reduction of the number of myonuclei and further
progressive muscle atrophy [42].
Despite sIBM not being an inherited Mendelian disease,
multiple genetic risk factors are being shown likely to play
important roles in the development and progression of
sIBM. A list of possible susceptibility genes that could
be important candidate genes for understanding the
pathogenesis of sIBM is shown in Table 3. Furthermore,
the prevalence of sIBM differs between different ethnic
populations. This is likely due to differences in genetic
makeup of different racial/ethnic groups and differences
in the environmental factors of different geographical
regions [29].
Genetic factors related to inflammatory changes in sIBM
Major histocompatibility complex
Garlepp and colleagues first reported the strong association
of HLA-DR3 and the extended 8.1 ancestral haplotype
(AH) with sIBM [57]. This association has subsequently
been confirmed in a series of further studies in Caucasians
with HLA-A*01, −B*0801, −DRB1*0301, −DRB1*0101,
−DRB1*1301, −DQB1*0201, −DQA1*05 [58-65]. Fur-
thermore, Rojana-udomsart and colleagues reported that
the risk factors HLA-DRB1*0301 and *1301 also influence
on the age at onset and the severity of muscle weaknessTable 3 Summary of possible susceptibility genes for sIBM ba
Classification Regions/G
Immune-associated genes MHC regio
Degenerative-associated genes APP gene [
PRNP gene
genes [53]
mtDNA-associated sequences/genes mtDNA de
POLG1, and[65]. These results indicate that the interactions at
HLA-DRB1 locus may contribute to both disease suscep-
tibility and clinical phenotype. Other alleles and haplo-
types have also been associated with increased risk of
sIBM, including the 35.2AH (HLA-B*3501, −DRB1*0101)
in Caucasians [63] and the 52.1AH (HLA-B*5201,
DRB1*1502) in Japanese [66]. Interestingly, a number
of HLA alleles and haplotypes, including HLA-DR53
and HLA-DRB1*0401, *0701, *0901, *1101, *1501, HLA-
DRB1*0301/*0401 and HLA-DRB1*0301/*0701 diplo-
types, and HLA-DRB1*1501, were found protective for
sIBM [58,65,67].
A potential region of MHC-associated susceptibility
genes was first defined between HLA-DR and C4 [43],
and then it was suggested in the border of the Class II and
III regions, between HLA-DRB1 and pre-B-cell leukemia
homeobox2 (PBX2, also known as HOX12) [63]. A further
recombination mapping was applied consisting of three
separate cohorts to refine the probably 8.1 AH-derived
sIBM susceptibility region from butyrophilin-like MHC
class II-associated gene (BTNL2) to telomeric of HLA-
DRB1 including three protein-coding genes – part of
BTNL2, HLA-DRA and HLA-DRB3 [68]. Other genes
in this region have also been considered as candidate
genes, such as notch 4 gene (NOTCH4; a transmembrane
receptor which regulates cell fate decisions), advanced
glycosylation end product-specific receptor gene (AGER,
previously known as RAGE), testis-specific basic protein
gene (C6orf10, also known as TSBP), and G-protein
signalling modulator 3 gene (GPSM3, previously known
as G18) [43,63].
Two NOTCH4 gene polymorphisms (rs422951 and
rs72555375) have shown a strong association (OR > 2)
with sIBM in two independent Caucasian cohorts [69].
These variants (or other variants in linkage disequilibrium
with them) may play a role in sIBM pathogenesis by gener-
ating antigenic peptides and can be regarded as markers for
sIBM susceptibility. They may also influence the binding
and affinity of notch 4 receptor and the presentation of the
gene product at the cell surface, respectively [69].
The MHC contains important genetic contents which
have been reported as being associated with sIBM and
among them 8.1AH which is predominant in Caucasians,
supporting an immune-mediated mechanism underlyingsed on current research and discussed in this review
enes
n [43]; NT5C1A gene [44].
45]; PSEN gene [46]; DYSF gene [47]; APOE gene [48]; MAPT gene [49];
[50]; SERPINA3 gene [51]; TARDBP gene [52]; hnRNPA1 and hnRNPA2B1
; C9orf72 [54].
letions [55]; Nuclear coding mitochondrial genes: TYMP, SLC25A4, C10orf2,
TOMM40 gene [16,56].
Gang et al. Orphanet Journal of Rare Diseases 2014, 9:88 Page 5 of 11
http://www.ojrd.com/content/9/1/88sIBM. Identification of the actual genes within the MHC
will be crucial to understand the role of MHC in the
pathogenesis of sIBM.
Other autoimmune factors
An autoantibody against the cytoplasmic 5′-nucleotidase
1A (cN1A; NT5C1A) was recently identified in sIBM by
two independent groups [44,70,71]. cN1A, as a member
of the family of 5′-nucleotidases, is a muscle-specific en-
zyme catalysing the hydrolysis of nucleotide to nucleo-
sides. It is involved in a variety of functions including
the physiological control of energy balance, metabolic
regulation, and cell replication [72]. By immunohisto-
chemistry, the accumulation of cN1A in perinuclear
regions and rimmed vacuoles in both sIBM and fIBM
muscle fibres indicates that cN1A protein might have a
potential contribution during myonuclear degradation
[44]. Although exome or whole genome sequencing
performed in 19 patients did not detect any protein-
altering variants in both NT5C1A and NT5C1B genes
[44], the genes encoding for the cN1A protein and a
functionally related protein, respectively, are still import-
ant genetic candidates for understanding the relationship
between sIBM autoimmunity and myofiber degeneration,
and worth further genetic investigation.
Candidate genetic factors related to degenerative
changes in sIBM
β-amyloid (APP) and presenilin (PSEN)
It has been widely recognized that there are abnormal
accumulations of beta-amyloid (Aβ) protein, N-terminal
and C-terminal of beta-amyloid precursor protein (APP),
and AβPP-mRNA in both sIBM and hIBM muscle fibres
[45,73,74]. Aβ42 is considered more cytotoxic and more
prone to self-association and oligomerization than Aβ40,
thereby exerting a detrimental role in AD brain [75].
Similarly, increased Aβ42 oligomers were demonstrated
preferentially in sIBM affected fibres [76] and also in
plasma from patients with sIBM [77]. These indicate that
the intra-muscle fibre accumulation of Aβ42 oligomers in
sIBM contributes to the pathogenic cascade [76]. The
mechanisms of overexpression of APP gene in sIBM have
not been fully understood. The fact that mutations in
exons 16 and 17 of APP gene have been found to be
pathogenic in AD, resulting in early-onset familial AD,
suggests that mutations in this gene might also play a role
in sIBM. In line with a previous small study [78], no coding
APP mutations were found in our 58 sIBM cases.
Abnormal accumulation of presenilin proteins occurs
in the brains of both sporadic and familial AD patients.
Autosomal dominant inheritance of mutations in prese-
nilin 1 (PSEN1) and presenilin 2 (PSEN2) genes are also
found to be responsible for early onset familial AD, with
mutations in PSEN1 gene as the most common cause[79]. The exact roles of presenilin are still not clear, but
it has been considered that mutations in presenilin genes
cause increased synthesis of the cytotoxic Aβ42 [80].
Abnormal accumulation of presenilin 1 protein was also
reported immunohistochemically in muscle fibres of both
sIBM and autosomal-recessive hIBM [46]. This indicates
there might be some similarities shared between AD and
IBM in pathogenic mechanism of presenilin deposits;
however, mutations in PSEN1 and PSEN2 have not been
investigated in either sIBM or hIBM cases.
Dysferlin (DYSF)
Dysferlin is a modular type II transmembrane protein
newly identified as a binding partner of AβPP that co-
aggregates with Aβ42 in sIBM muscle fibres [47]. In normal
human muscle, dysferlin is immunohistochemically present
in the muscle fibre sarcolemma and involved in plasma-
lemmal repair after injury as well as in T-tubule contrac-
tion and calcium homeostasis. Mutations in DYSF gene are
known to cause a range of autosomal recessive myopathies,
called dysferlinopathies including Miyoshi myopathy and
limb girdle muscular dystrophy type 2B (LGMD2B) [81].
Similarly to dysferlinopathies, dysferlin is prominently
reduced in the muscle fibre sarcolemma in sIBM muscle
biopsies [47]. In addition, there is abnormal distribution of
dysferlin into the cytoplasmic protein aggregates which
co-localise with Aβ42 aggregates. Accordingly, it is sug-
gested that mutation(s) in DYSF gene might link to the
pathogenesis of sIBM though the possible mechanisms is
unknown [47].
Apolipoprotein E (APOE)
ApoE protein deposits but not mRNA have been identi-
fied in both sIBM and hIBM muscle fibres [82,83]. The
APOE ε4 allele is recognized to be an important risk factor
for developing late-onset AD. Several studies have been
carried out to investigate the roles of APOE alleles in
sIBM. Only one study of a cohort of 14 Australian sIBM
patients suggested that ε4 allele may be a susceptibility
factor for the development of sIBM [84]. However, this
association was not replicated in subsequent studies in
Europe and USA [48,51,85-87]. A study in a larger cohort
(N = 57) [48], including also a meta-analysis, argues
against a role of APOE ε4 allele as a susceptibility factor
for developing sIBM. However, the authors demonstrated
a non-significant trend towards an earlier age at onset in
patients with the APOE ε2 allele [48].
Our preliminary data (58 sIBM cases from UK, USA
and two European countries) is consistent with the above
meta-analysis with respect to the association with APOE
ε4 allele. Interestingly, we found a statistically significant
decreased frequency of APOE genotype ε2/ε3 (p-value =
0.026) in the patient group compared with our British
control individuals (unpublished data), and thus we found
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developing sIBM (Table 4). ApoE may play a role in the
AβPP pathway, as ApoE protein was found to co-localise
with Congo red-positive β-amyloid deposits in sIBM cases.
However, it is difficult to elucidate actual influences of
APOE alleles on the development of sIBM, mainly because
of the genetic heterogeneity of this disease.Phosphorylated Tau (MAPT)
Accumulation of phosphorylated-tau is widely known to be
another major protein present in sIBM muscle aggregates,
which is strikingly similar with those found in taupathies
which share hyperphosphorylated deposited tau protein in
the brain [88]. Different microtubule-associated protein
tau (MAPT) gene mutations have been identified in many
different tauopathies including AD, frontotemporal de-
mentia and Parkinsonism linked to chromosome 17
(FTDP-17), progressive supranuclear palsy (PSP) and
corticobasal degeneration (CBD). The majority of them
affect exons 9–13 [89]. In addition to MAPT mutations, a
common extended haplotype (H1) in MAPT appears to be
a risk factor for sporadic PSP [49]. A 238 bp deletion in
MAPT intron 9 is inherited as a part of the less common
H2 sub-haplotype [49]. We analysed this deletion poly-
morphism (del-In9) in 81 sIBM DNA cases and 159 British
healthy controls, but no significant differences were found
between the two groups.Alpha-1-antichymotrypsin (SERPINA3)
Alpha-1-antichymotyrpsin (α1ACT; SERPINA3, previously
known as ACT) is considered a major acute-phase protein
and belongs to the serpin superfamily specifically inhibiting
serine proteases. Similarly to AD brains, abnormal accu-
mulations of α1ACT, located closely with β-amyloid pro-
tein containing ubiquitinated amyloid plaques, have been
described in sIBM muscle [90]. Though genotype of SER-
PINA3/AA (rs4934) was found to alter the AD risk associ-
ated with APOE ε4/ε4 genotype [91], this correlation was
not found in a cohort of 35 sIBM patients [51]. It mightTable 4 Frequency of APOE alleles in different studies
Study Country
Garlepp et al. [84] Australia
Harrington et al. [86] UK
Love et al. [87] UK
Askanas et al. [85] USA
Gossrau et al. [51] Germany
Needham et al. [48] Australia
Present study (our unpublished data)* UK, USA and two European countri
*All participants gave their written informed consent and the study was approved b
Square (REC reference: 12/LO/1557).also be due to the small size of the patients’ cohort, which
indeed lacked cases with the APOE ε4/ε4 genotype.
Prion (PRNP)
Prion protein and mRNA (normal cellular isoform -
PrPc) have been described as being abnormally accu-
mulated in vacuolated muscle fibres in both sIBM and
hIBM [92,93]. Lampe et al. reported that homozygosity
for methionine at codon 129 (M/M) of the prion pro-
tein (PRNP) gene was more prevalent in sIBM (14 of
22 patients, 64%), when compared with controls [50].
But this finding was not replicated in later studies with
larger cohorts (51.2% M/M [94] and our unpublished
data 40% M/M).
TAR DNA-binding protein (TARDBP) and other heterogeneous
nuclear ribonucleoproteins (hnRNPs)
A predominantly nuclear heterogeneous nuclear ribo-
nucleoprotein (hnRNP) TAR DNA-binding protein-43
(TDP-43) is found as a major component of ubiquiti-
nated inclusions in amyotrophic lateral sclerosis (ALS)
and frontotemporal lobar dementia (FTLD-U). Mutations
in TARDBP have been detected in both sporadic and fa-
milial forms of ALS [95]. Several recent studies [52,96-98]
have detected sarcoplasmic TDP-43 inclusions in sIBM
muscle fibres, which contrast with predominately nuclear
immunostaining observed in normal tissue [52]. Similar
TDP-43 deposits were also identified in IBMPFD, hIBM2
and other myofibrillar myopathies [97]. The similarities
between these changes in sIBM muscle and those seen in
brain tissue of ALS and FTLD-U suggest that sIBM may
share some pathological pathways with these two diseases.
TDP-43 could potentially interfere with the normal
regulation of gene expression at the transcriptional
level, regulating gene splicing and stabilizing extranu-
clear RNAs that maintain myofibre protein production.
But exonic mutations in TARDBP gene have not yet
been examined in a sIBM.
Abnormalities in the distribution of two other hnRNPs,
hnRNPA1 and hnRNPA2B1, were identified in sIBMNumber of alleles
(cases/controls)
ε2 allele
(controls)
ε3 allele
(controls)
ε4 allele
(controls)
28/344 0.07 (0.061) 0.69 (0.811) 0.29 (0.128)
22/116 0 (0.086) 0.818 (0.767) 0.182 (0.147)
82/5008 0.05 (0.08) 0.79 (0.79) 0.16 (0.13)
22/70 0.09 (0.10) 0.86 (0.79) 0.05 (0.11)
70/112 0.1 (0.036) 0.757 (0.848) 0.143 (0.116)
114/344 0.044 (0.061) 0.825 (0.811) 0.132 (0.128)
es 116/1540 0.07 (0.13) 0.77 (0.73) 0.16 (0.14)
y the National Research Ethics Service (NRES) Committee London – Queen
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were also depleted in myonuclei and form part of sarco-
plasmic aggregates in sIBM muscle [53]. This further sug-
gests that sIBM myofibre injury might be linked to
disrupted RNA homeostasis [99], since there is depletion
of these genes at the protein but not at the mRNA level
[53]. Mutations in hnRNPA1 and hnRNPA2B1 have been
identified in familial multisystem proteinopathy with similar
myonuclei depletion and sarcoplasmic aggregates [100].
These genes constitute, therefore, good candidates to be
further investigated in sIBM patients.
C9orf72 repeat
An expanded GGGGCC hexanucleotide repeat in the
noncoding region of C9orf72 has been identified as the
most common genetic cause of familial ALS, FTLD or a
combination of both phenotypes and TDP-43-based
pathology (FTLD-TDP) [54]. In a recent study, it was
suggested that mutations in C9orf72 may involve dis-
rupted protein degradation [101]. Therefore, we hypoth-
esized that genetic defects in C9orf72 might also play a
role in the pathogenesis of sIBM. Fifty-eight sIBM cases
were analysed for C9orf72 repeat by our group, but no
expanded repeats were found.
Mitochondrial DNA abnormalities (mtDNA deletions)
and sIBM
Mitochondrial abnormalities are another important patho-
logical feature in sIBM muscle biopsies, consisting of
ragged-red fibres and mostly showing enzyme histochem-
ical deficiency of COX activity. These changes are more
prevalent in sIBM than in polymyositis, dermatomyositis
and normal ageing muscle fibres [102]. It is therefore of
great interest to investigate another group of susceptibility
factors – mitochondrial DNA (mtDNA). An accumulation
of mtDNA molecules with large-scale deletions was found
in many COX-deficient ragged-red fibres of sIBM patients
(e.g. [103]), with multiple different deletions in different
muscle fibres but usually one predominant type of mtDNA
deletion present in each COX-deficient fibre [55,104].
Thirty-three different deletions were identified by sequen-
cing four patients with sIBM. The majority of mtDNA de-
letion breakpoints identified in sIBM muscle fibres span
from the region of nt8029-8032 to the region of nt16066-
16078 [55] which are similar to those found in normal
ageing and in autosomal dominant progressive external
ophthalmoplegia (adPEO). These indicate that there may
be a shared mechanism for the generation of mtDNA
deletions in normal ageing, sIBM and adPEO. AdPEO
and other hereditary disorders with multiple mtDNA
deletions have been found associated with mutations in
some nuclear genes, such as thymidine phosphorylase
gene (TYMP, previously known as ECGF1), solute car-
rier family 25 (mitochondrial carrier; adenine nucleotidetranslocator) member 4 gene (SLC25A4, previously known
as ANT1), chromosome 10 open reading frame 2 (C10orf2)
and polymerase gamma 1 (POLG1), which are important
for mtDNA maintenance and replication [16]. Putative
defects in these nuclear genes may directly or indirectly
affect sIBM muscle. Notwithstanding no mutations in
these genes were identified in sIBM cases, there is not
enough evidence to exclude these genes as possible
candidates. The reason for the accumulation of mtDNA
deletions in sIBM muscle fibres is still unclear and no cor-
relation between the presence of deletions and gender,
age, or the main clinical features has been found so far
[16,104]. But similar to the normal ageing muscle, mtDNA
mutations in sIBM may be involved in the muscle atrophy
and weakness.
In addition to mtDNA deletions, mutations at mtDNA
nucleotide positions 3192, 3196, 3397 and 4336, which
are associated with late-onset AD, are possible risk fac-
tors for sIBM. In sIBM cases only the frequency of the
common 16311C variant has been found more fre-
quent than in AD and controls, but these differences
were not statistically significant [105]. Interestingly, all
the patients with 16311C variant were HLA-DR3 posi-
tive [105], suggesting that there might be some inter-
action between this variant and HLA-DR3, which is in
a genomic region strongly associated with sIBM. Fur-
ther studies are required to investigate whether this
variant plays a pathogenic role in sIBM and/or its pos-
sible interaction with other genetic factors.
Recently a gene called ‘Translocase of Outer Mito-
chondrial Membrane 40’ (TOMM40) which is adjacent
to and in linkage disequilibrium with the APOE locus
on chromosome 19, has been implicated in AD [106].
TOMM40 encodes an outer mitochondrial membrane
translocase facilitating the transport of unfolded pro-
teins such as amyloid-β from the cytosol into the mito-
chondrial intermembrane space [107]. A polyT repeat,
an intronic polymorphism (rs10524523), in the TOMM40
gene together with the APOE genotypes has been shown
to influence disease susceptibility of AD [108]. It has
been reported that carriers of the APOE ε3 allele with
a very long (VL) polyT repeat alleles in TOMM40
had reduced risk of sIBM compared to controls, and
this was also associated with a later age at onset of
symptoms [56]. The rs10524523 may modulate ex-
pression levels of TOMM40 and/or APOE to influence
disease susceptibility. This also comes to a hypothesis
that genetic variants of TOMM40 could be associated
with altered mitochondrial pore function and transport
of proteins into mitochondria. This could result in
energy metabolism changes and increased reactive oxy-
gen species formation, further contributing to the im-
pairment in mitochondria and degeneration in muscle
fibres [56].
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sequencing
Over the past five years, next-generation sequencing
technologies have already shown considerable promises
in the identification of rare variants associated not only
with Mendelian but also with complex diseases. For ex-
ample, rare variants in TREM2 were recently found to
be associated with increased risk of Alzheimer’s disease
by using whole-genome and whole-exome sequencing
(WES) [109]. Up to recently, most genome-wide studies
were based on common SNPs thought to have small ef-
fects on disease, and thus large size cohorts were needed
to find positive associations. The advent of WES enables
now the identification of rare coding variants which are
likely functional and likely show stronger effects, increas-
ing the likelihood of detecting disease associated variants.
This advantage of WES is particularly important for rare
diseases like sIBM where the number of cases is probably
not large enough for a conventional genome-wide associ-
ation study (GWAS). Moreover, WES also enables the
analysis of the whole set of genes belonging to candidate
biochemical pathways in a very quick and cost effective
way. These techniques have the potential to yield very
interesting results, especially to uncover previously over-
looked biological processes of complex disorders, linking
results from studies on molecular data, clinical pheno-
types and biological disease pathways. The description of
mutations in the same genes causing different diseases
highlights the important role of next-generation sequen-
cing in uncovering pleiotropic events, particularly in neu-
rodegenerative disorders [110]. Therefore, based on the
International IBM Consortium Genetic Study (IIBMCGS),
WES will be performed for 200 sIBM cases and 200 nor-
mal muscle controls by our group. So far, only 19 sIBM
cases have been exome sequenced in an American group
[44], but no further data has been reported. Our study,
currently with 160 recruited sIBM cases, is the largest
sIBM cohort to date. We expected to identify a number of
rare sIBM variants that cluster in disease associated genes.
Replication of these findings will be verified in a further
700 sIBM cases and 2200 controls. It is also worthwhile
to combine with other techniques, such as genotyping,
haplotyping for HLA gene, fragment analysis for repeat
variants, and comparative genomic hybridization (CGH)
analysis for copy number variants which cannot be de-
tected by WES.
In the future, besides genetic defects identified in sIBM,
RNA sequencing in muscle tissue and lymphoblast lines
will identify transcriptomic profiles and expression quanti-
tative trait loci (eQTL) in sIBM and other inflammatory
myopathies. The application of RNA sequencing will also
allow us to study and dissect splicing abnormalities which
may not be detected by exon arrays. Investigating the
transcriptomic and genomic factors will be important inrevealing dysregulated molecular pathways in these dis-
orders, identifying a diagnostic signature in blood and
revealing biomarkers for future therapeutic strategies. A
searchable database to the research community is also
planned to build up to integrate WES, RNA sequencing
and eQTL data, further to aligned with the biobank data-
base with disease progression, response to treatment and
muscle imaging.
Conclusion
In conclusion, sIBM remains an enigmatic muscle dis-
order even though it has been about half a century since
the first case was described. The primary pathogenesis of
sIBM is still controversial, but it is more likely to due to
multifactorial mechanisms, including immune changes,
degenerative changes, mitochondrial abnormalities and
the ageing milieu in the muscle fibres, which involve a
complex interaction between environmental triggers
(possibly viral) and genetic susceptibility. Despite the
strikingly phenotypic similarities between sIBM muscle
fibres and the brains of AD, research on the candidate
genes encoding the deposited proteins have not shown
any positive result so far. Genes located within the MHC
region are still the most strongly associated candidates
with sIBM. Genes linked to hIBM and pathologically
sIBM-like myopathies may provide important clues for
sIBM genetic research. Effective WES and RNA sequen-
cing analysis of a large sIBM cohort will significantly
contribute to our knowledge in this under-explored area.
Search strategy
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generated on the basis of relevance to the topics covered
in this Review.
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